Shaimaa et al. reported that MCM2 was an important downstream target of CDC7, as CDC7 significantly improved the chemoresistance of SKCM to BRAFV600E-specific inhibitors, indicating that MCM2 may be a potential therapeutic target for cancers (Gad et al., 2019). Here, MCM2 is linked to cancer.